Chat
Quote Me Now
Single Step Guaranteed Knockdown No transfection reagents needed Ideal for cellular and animal studies
Chat

Featured Products

AUMsilence
mRNA knockdown
AUMinc
lncRNA knockdown
AUMantagomir
miRNA inhibitor
Preclinical Studies
in vivo delivery
Find Out Which Product Is Right For You

Publications

PUBLISHED IN iScience

LET-dependent low dose and synergistic inhibition of human angiogenesis by charged particles: validation of miRNAs that drive inhibition

Wuu, Y-R. et al. 3 November 2020
PUBLISHED IN Nature Communications

Endogenous antisense RNA curbs CD39 expression in Crohn’s disease

Harshe, R.P. et al. 24 August 2020
PUBLISHED INiScience

Alterations of redox and iron metabolism accompany the development of HIV latency

Shytaj, I. L. et al. 5 May 2020
PUBLISHED IN Behavioral Brain

Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats

Solanki, N. et al. 10 April 2020
PUBLISHED INiScience

Alterations of redox and iron metabolism accompany the development of HIV latency

Shytaj, I. L. et al. 5 May 2020
PUBLISHED IN Behavioral Brain

Administration of a putative pro-dopamine regulator, a neuronutrient, mitigates alcohol intake in alcohol-preferring rats

Solanki, N. et al. 10 April 2020

Why Use FANA Oligos for RNA Silencing?

FANA ASOs vs. siRNAs
The basics
Not Required Transfection Reagents Required
FANA proprietary technology allows very high specificity for the target RNA Specificity siRNA grade specificity
None RISC associated Off target effects Yes
Easy and convenient single step process Transition from basic cell lines to primary cells to animal models Require extensive optimization and use of delivery reagents
Ease of use in different model systems
Easy to use. No transfection reagents required. Mix FANA oligos with the cells Basic Cell lines Need transfection reagents. Transfection reagent based optimization required
Easy to use. No transfection reagents required. Mix FANA oligos with the cells Primary cells and difficult to transfect cells Need transfection reagents that kills the sensitive cells and sometimes alter the biology
Can work in fish models (example zebrafish) Fish models Not recommended for fish models
Key Attributes
Non-toxic Toxicity Can be toxic
Resistant to degradation by serum and cellular nucleases Stability Moderate stability
Minimal resources needed and easy to optimize Resources and time saving Require additional reagents and machines. Time consuming optimization
Up to 80% more cost effective in terms of time and money. Cost saving Expensive to use

Comparison of FANA ASO and siRNA mode of action

As opposed to the RNAi pathway (involving RISC) FANA single-stranded antisense oligonucleotides use RNase H-mediated cleavage. This mode of mRNA knockdown is simpler than siRNA mediated knockdown and eliminates RISC-associated off-target effects often observed with siRNA. Unlike siRNAs that are processed in the cytoplasm, FANA oligos can go into the nucleus and can be used to target RNA present within the nucleus. Most importantly FANAs can be self delivered and do not need transfection reagents or delivery agents.

Comments on FANA ASO Technology

Publications on FANA

Publications from 2019

Karyn Schmidt, Johanna S. Carroll, Elaine Yee, Dolly D. Thomas, Leon Wert-Lamas, Steven C. Neier, Gloria Sheynkman, Justin Ritz, Carl D. Novina. The lncRNA SLNCR Recruits the Androgen Receptor to EGR1-Bound Genes in Melanoma and Inhibits Expression of Tumor Suppressor p21, Cell Reports, Volume 27, Issue 8,2019, 2493-2507.e4, SSN 2211-1247, https://doi.org/10.1016/j.celrep.2019.04.101

View Publication
Publications from 2019

Mayumi Takahashi, Haitang Li, Jiehua Zhou, Pritsana Chomchan, Veenu Aishwarya, Masad J. Damha, John J. Rossi, Dual mechanisms of action of self-delivering, anti-HIV-1 FANA oligonucleotides as a potential new approach to HIV therapy, Molecular Therapy - Nucleic Acids, 2019.https://doi.org/10.1016/j.omtn.2019.07.001

View Publication
Publications from 2019

Suwanmanee, S., Mahakhunkijcharoen, Y., Ampawong, S., Leaungwutiwong, P., Missé, D., Luplertlop, N. (2019). Inhibition of N‐myristoyltransferase1 affects dengue virus replication. MicrobiologyOpen; e831. https://doi.org/10.1002/mbo3.831

View Publication
Publications from 2018

Chorzalska, A., Morgan, J., Ahsan, N., Treaba, D. O., Olszewski, A. J., Petersen, M., … Dubielecka, P. M. (2018). Bone marrow-specific loss of ABI1induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood, 132(19), 2053–2066. doi:10.1182/blood-2018-05-848408

View Publication
Publications from 2018

Frank, S., Ahuja, G., Bartsch, D., Russ, N., Yao, W., Kuo, J. C. C., ... & Messling, J. E. (2018). yylncT Defines a Class of Divergently Transcribed lncRNAs and Safeguards the T-mediated Mesodermal Commitment of Human PSCs. Cell stem cell, 24(2), 318-327. doi:10.1016/j.stem.2018.11.005.

View Publication
Publications from 2018

Ludlow, A. T., Wong, M. S., Robin, J. D., Batten, K., Yuan, L., Lai, T. P., … Shay, J. W. (2018). NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nature communications. Nature Communications, 9(1), 3112. doi:10.1038/s41467-018-05582-x

View Publication

Award Winning Technology

We would like to congratulate Dr. Mayumi Takahashi, Beckman Research Institute of City of Hope, California on receiving the Dr. Alan M. Gewirtz Memorial Scholarship. This award is given to outstanding scientists and recognizes their contributions in the field of oligonucleotide therapeutics. In her work, Dr. Takahashi used FANA ASOs to inhibit HIV-1 replication with a goal to develop FANA based therapeutics for HIV.

Protocols

Much more convenient than siRNA, shRNA or CRISPR

in vitro

No Transfection Reagents Needed (Self-Delivery Or Gymnosis)

We take pride in having the simplest protocol for RNA silencing studies. FANA oligos can work with any cell type without causing toxicity. FANA can work with easy to transfect, hard to transfect (like primary cells, b-cells, t-cells, neurons etc.) and highly sensitive patient samples.

More..

in vivo

No Delivery Vehicle, Formulations Or Conjugates Needed

It is recommended to test a few doses of FANA oligos. Recommended dose is between 3 – 30 mg/kg in mice. Administration routes: Depending upon your experimental purpose you may choose from Subcutaneous, Intrathecal, Oral or Intestinal.

More..

About us

AUM BioTech is a Philadelphia based biotechnology company with a revolutionary nucleic acids platform in the gene silencing and regulation space. AUM’s FANA RNA silencing and regulation technology can be used to very efficiently target a variety of RNA modalities like – mRNA, microRNA and long non-coding RNA. FANA technology can be used for discovery, translational and potentially for therapeutic development. Considering the versatility of our next generation RNA silencing and regulation platform AUM is now making the FANA technology available to biomedical researchers across the globe.

RNA Silencing Tech Comparison

  • Not required
  • Transfection reagents
  • Required
  • High
  • Efficiency in hard-to-transfect cells
  • Low to moderate
  • None
  • Toxicity
  • Probable due to use of transfection reagents
  • Very high
  • Resistance to nucleases
  • Moderate
  • Easy and convenient 1-step process
  • Transition from cell culture to in vivo models
  • Require extensive optimization use of delivery reagents
  • No
  • RISC-associated off-target effects
  • Yes
  • Very high
  • Stability
  • Moderate
  • High binding affinity and specificity to the target RNA
  • Specificity
  • siRNA-grade binding affinity and specificity
  • mRNA / lncRNA / miRNA
  • Targets
  • Genomic DNA
  • Genomic DNA
  • RNA
  • Target restrictions
  • PAM sequence
  • PAM sequence
  • Self-delivery
  • Cell delivery
  • Viral lipofection nucleofection
  • Required
  • RNase H catalysis or steric blocking
  • Mode of action
  • Cas9 catalysis
  • Steric blocking
  • Reversible knockdown
  • Phenotype
  • Irreversible knockout
  • Reversible knockdown
  • High (≥80%)
  • Efficiency
  • Low
  • Varies
  • 1-2 days
  • Time
  • 1-3 months
  • 3-5 days
  • Low
  • Cost
  • High
  • High
  • Not required
  • Viral vectors
  • Required
  • Easy to use and no viral vectors required
  • Primary cells and hard-to-transduce cells
  • No transduction needed
  • Non-toxic
  • Toxicity
  • Can be toxic
  • ≥30% more cost effective both in terms of time and money
  • Time
  • Longer protocols and optimization
  • Easy and convenient 1-step process
  • Transition from cell culture to in vivo models
  • Require extensive optimization and need viral vectors
  • No
  • RISC-associated off-target effects
  • Yes
  • Easy to use and no viral vectors required
  • Basic cell lines
  • Need viral vectors and optimization
  • High binding affinity and specificity to the target RNA
  • Specificity
  • shRNA-grade binding affinity and specificity

Protocols

We take pride in having the simplest protocol for RNA silencing studies. FANA ASOs can work with any cell type without causing toxicity. FANA ASOs can work with easy to transfect, hard to transfect (like primary cells, b-cells, t-cells, neurons etc.) and highly sensitive patient samples.

Read More

Testimonials

“We have tested FANA inhibitors in primary neuronal cultures and in the adult mouse brain to reduce the levels of miR-34c. Looks as if FANA inhibitors are more potent than Qiagen. The reduction of miR-34c in vivo after injection of FANA ASO is very dramatic.”

ANDRE FISCHER, PHD Professor for Epigenetics in Brain Diseases Department for Psychiatry and Psychotherapy University Medical Center Göttingen German Center for Neurodegenerative Diseases (DZNE)

Read More
FANA ASO
AUM PRODUCTS
RESOURCES
legal
get in touch
2021 AUM BIOTECH, LLC.